ACURASYS: Neuromuscular Blockers in Early Acute Respiratory Distress Syndrome
Clinical Question
In patients with moderate-severe ARDS does the early use of a neuromuscular blocking agent improve mortality?
Type of Trial: RCT - computer generated - stratified by ICU
Blinding: double blinded; computer-generated random-number tables with telephone system to ensure allocation concealment
Setting: 20 ICUs in France from March 2006-March 2008
Intention to treat analysis: yes
PICO
Population:
339 adult patients with moderate/severe ARDS as defined by ET mechanical ventilaton for acute hypoxemic respiratory failure and the presence of all the following within <48h: P/F<150 with PEEP>/=5, tidal volume 6-8cc/kg. Bilateral pulm infiltrates and absence of clinical evidence of left atrial hypertension
Excluded if:
continuous infusion of neuromuscular blocking agent at enrolment
pregnancy
raised ICP
longterm O2 therapy or home ventilation, severe chronic liver disease
bone marrow transplant or chemotherapy induced neutropenia
pneumothorax
expected duration of mechanical ventilation <48 hours or decision to withhold life sustaining treatment
actual body weight >1kg/cm height
Intervention:
Neuromuscular blocking agent for 48 hours - cisatracurium 15mg bolus followed by infusion of 37.5mg/hr for 48h
Control:
Placebo. All patients on volume assisted control ventilation, tidal volumes 6-8 cc/kg of predicted body weight, target SpO2 88-95% or PaO2 55-80mmHg, PEEP adjusted acording to ARMA trial
llowed two open-label boluses of 20mg cisatracurium if plateau pressue >32cmH20 despite increasing sedatives and decreasing tidal volume/PEEP
Use of peripheral nerve stimulators was not permitted
Outcome:
Primary outcome: adjusted 90 day mortality significantly lower in cisatracurium group
Secondary outcomes:
actual 90 day mortality - no significant differences (31.6% in intervention vs 40.7% in control, p=0.08)
Comparing cisatracurium group vs. placebo
significantly more patients in placebo group had
barotrauma
pneumothraces
received open-label cistracurium in 1st 48 hours following inclusion
significantly more patients in cisatracurium group had
more days without non-respiratory organ failure
No significant difference in incidence of ICU-acquired paresis
Sub-group analysis based on PaO2:FiO2 ratio
probability of survival to day 90 (log-rank test)
PaO2:FiO2 <120, p=0.051
PaO2:FiO2 ≥120, p=0.74
Conclusions
In patients with severe ARDS, early administration of a neuromuscular blocking agent improved the adjusted 90-day survival and increased the time off the ventilator without increasing muscle weakness
Strengths
Randomized controlled trial
Double blinded (Clinicians likely to have been able to determine clinically if patient had received neuromuscular blocking agents and therefore may have treated patients differently)
Multi-center
Protocolised ventilation strategy
Weaknesses
With lower than expected mortality the power of the study is much lower than predicted
The use of adjusted mortality for primary outcome was not specified when registering the trial on clinical trials
10% of patients excluded due to ‘other reason’
Some aspects of management are not comparable to current Piedmont practice (21% swanz-ganz, 30% nitric oxide)
Trend towards significant difference in use of corticosteroids
Take Note
Further studies to confirm this study would be beneficial - specifically one with standardized protocols for the use of co-interventions such as proning, steroids
Overall improves mortality
Sources:
https://www.thebottomline.org.uk